Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Halimatou Diawara(Unknown), Amatigué Zéguimé, Alassane Dicko(Ministère de la Santé et de l'Hygiène Publique), Natasha KC(Sanaria), Tooba Murshedkar(Sanaria), Ibrahim H. Soumbounou, Thomas L. Richie(Sanaria), Zonghui Hu(National Institutes of Health), Santara Gaoussou(University of Bamako), Djibrilla Issiaka, Rathy Mohan(National Institutes of Health), Patrick E. Duffy(National Institute of Allergy and Infectious Diseases), Irfan Zaidi(National Institutes of Health), Blair J. Wylie(Columbia University Irving Medical Center), Seydou Traoré, Justin Doritchamou(National Institutes of Health), Oumar Attaher(University of Bamako), Michal Fried(National Institutes of Health), Agnes Mwakingwe-Omari(National Blood Clot Alliance), Sara A. Healy(National Institutes of Health), Viyada Doan(National Institutes of Health), Jing Wang(Wenzhou Medical University), Kelly M. Rausch(National Institutes of Health), Almahamoudou Mahamar(University of Bamako), Peter F. Billingsley(Sanaria), B Kim Lee Sim(Sanaria), Robert Morrison(National Institute of Allergy and Infectious Diseases), Amagana Dolo(University of Bamako), Stephen L. Hoffman(Sanaria), Aye Diallo(National Institutes of Health)
The Lancet Infectious Diseases
August 14, 2024
Cited by 31


Related Papers